Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are
established driver mutations in non-small cell lung cancer (NSCLC) 1 , 2 – 3 . Targeted …

Purpose: Osimertinib was initially approved for T790M-positive non–small cell lung cancer (NSCLC)
and, more recently, for first-line treatment of EGFR-mutant NSCLC. However, …

Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene
alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has …

In this work, we identify co-occurring genomic alterations in KEAP1 , SMARCA4 , and CDKN2A
as independent determinants of poor clinical outcomes with KRAS G12Ci monotherapy …

Introduction Programmed death-ligand 1 (PD-L1) expression may vary in different disease
sites and at different time points of the disease course. We aimed to investigate PD-L1 …

The role of combination chemotherapy with immune checkpoint inhibitors (ICI) (ICI-chemo)
over ICI monotherapy (ICI-mono) in non-small cell lung cancer (NSCLC) remains …

Background Only around 20–30% of patients with non-small-cell lung cancer (NCSLC) have
durable benefit from immune-checkpoint inhibitors. Although tissue-based biomarkers (eg, …

Methylthioadenosine phosphorylase, an essential enzyme for the adenine salvage pathway,
is often deficient (MTAP def ) in tumors with 9p21 loss and hypothetically renders tumors …

Purpose: Radiotherapy with or without chemotherapy is a mainstay of treatment for locally
advanced non–small cell lung cancer (NSCLC), but no predictive markers are currently …

Purpose: The optimal systemic treatment for pulmonary large-cell neuroendocrine carcinoma
(LCNEC) is still under debate. Previous studies showed that LCNEC with different genomic …